Familial Mediterranean fever (FMF) is an inherited disorder caused by the gain of function mutations in MEFV (MEditerranean FeVer) gene loci. FMF affects more than 100,000 people worldwide and generally seen in the eastern Mediterranean region and causes the lifelong diseases which have a significant effect on the patient's life quality and health systems. The identification of low penetrant or heterozygous MEFV gene mutations in clinically diagnosed FMF patients was considered that epigenetic or environmental factors may display a role in FMF pathogenesis. Epigenetics might be defined as heritable changes that affect gene expression without any changes in the genome. MicroRNAs (miRNAs) are the main group of small noncoding RNAs, and an important element of epigenetic mechanisms and their discoveries revolutionized our knowledge about biological processes, such as malignant, infectious and autoimmune mechanisms, and contributed to the development of the epigenetic areas. In this review, the studies focusing on the roles of miRNAs in FMF pathogenesis in the last decades were examined and the importance of miRNAs as therapeutic agents which are promising for diagnosis and treatment was discussed.
{"title":"Familial Mediterranean fever and microRNAs","authors":"Aslihan Esra Bildirici","doi":"10.1111/iji.12640","DOIUrl":"10.1111/iji.12640","url":null,"abstract":"<p>Familial Mediterranean fever (FMF) is an inherited disorder caused by the gain of function mutations in <i>MEFV (MEditerranean FeVer)</i> gene loci. FMF affects more than 100,000 people worldwide and generally seen in the eastern Mediterranean region and causes the lifelong diseases which have a significant effect on the patient's life quality and health systems. The identification of low penetrant or heterozygous <i>MEFV</i> gene mutations in clinically diagnosed FMF patients was considered that epigenetic or environmental factors may display a role in FMF pathogenesis. Epigenetics might be defined as heritable changes that affect gene expression without any changes in the genome. MicroRNAs (miRNAs) are the main group of small noncoding RNAs, and an important element of epigenetic mechanisms and their discoveries revolutionized our knowledge about biological processes, such as malignant, infectious and autoimmune mechanisms, and contributed to the development of the epigenetic areas. In this review, the studies focusing on the roles of miRNAs in FMF pathogenesis in the last decades were examined and the importance of miRNAs as therapeutic agents which are promising for diagnosis and treatment was discussed.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 6","pages":"273-280"},"PeriodicalIF":2.2,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iji.12640","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41129592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Quan Yao Ho, Chew Yen Phang, Ian Tatt Liew, May Ling Lai, Carolyn Shan-Yeu Tien, Sobhana Thangaraju, Marieta Chan, Terence Kee
Human leucocyte antigen (HLA) alleles may generate antibodies that are undetectable by routine single-antigen beads (SABs) assays if their unique epitopes are unrepresented. We aimed to describe the prevalence and explore the potential impact of unrepresented HLA alleles in standard SAB kits in our cohort. All individuals who had undergone two-field HLA typing (HLA-A/B/C/DRB1/DQA1/-DQB1/-DPA1/-DPB1) from February 2021 to July 2023 were included. Two-field HLA-DRB3/4/5 typing was imputed. Each unrepresented allele was compared with the most similar represented allele in the standard LABScreen, LABScreen ExPlex (One Lambda) and the LIFECODES (Immucor) SAB kits. Differences in eplet expression (HLA Eplet Registry) were identified. Differences in three-dimensional molecular structures were visualized using generated models (SWISS-MODEL). Two-field HLA typing was performed for 116 individuals. Overall, 16.7% of all HLA alleles, found in 36.2% of individuals, were unrepresented by all SAB test kits. Four eplets, found in 12.9% of individuals, were unrepresented in at least 1 SAB kit. Non-Chinese individuals were more likely to have unrepresented HLA alleles and eplets than Chinese individuals. There were differences in HLA allele and eplet representation amongst the different SAB test kits. Use of supplementary SAB test kits may improve HLA allele and eplet representation. Although some HLA alleles were unrepresented, most epitopes were represented in current SAB kits. However, some unrepresented alleles may contain epitopes which may generate undetectable antibodies. Further studies may be needed to investigate the potential clinical impact of these unrepresented alleles and eplets, especially in certain ethnic populations or at-risk individuals.
人类白细胞抗原(HLA)等位基因可能产生抗体,无法检测常规的单抗原珠(SABs)检测,如果其独特的表位是不代表。我们的目的是描述我们的队列中标准SAB试剂盒中未代表的HLA等位基因的患病率并探索其潜在影响。所有于2021年2月至2023年7月接受HLA双区分型(HLA- a /B/C/DRB1/DQA1/-DQB1/-DPA1/-DPB1)的个体均被纳入研究。输入双域HLA-DRB3/4/5分型。将每个未代表的等位基因与标准LABScreen、LABScreen ExPlex (One Lambda)和LIFECODES (Immucor) SAB试剂盒中最相似的代表等位基因进行比较。确定了eplet表达差异(HLA eplet Registry)。使用生成的模型(SWISS-MODEL)可视化三维分子结构的差异。对116例患者进行HLA双区分型。总体而言,在36.2%的个体中发现的16.7%的HLA等位基因未被所有SAB检测试剂盒所代表。在12.9%的个体中发现的四个小体在至少一个SAB试剂盒中没有代表。与中国人相比,非中国人更有可能具有未被代表的HLA等位基因和等位基因。不同的SAB检测试剂盒在HLA等位基因和等位基因的表达上存在差异。使用补充的SAB检测试剂盒可以改善HLA等位基因和等位基因的表达。虽然一些HLA等位基因未被代表,但大多数表位在目前的SAB试剂盒中都有代表。然而,一些未代表的等位基因可能含有可能产生无法检测到的抗体的表位。可能需要进一步的研究来调查这些未代表的等位基因和等位基因的潜在临床影响,特别是在某些种族人群或高危个体中。
{"title":"Unrepresented human leucocyte antigen alleles in single-antigen bead assays: A single-centre cohort study","authors":"Quan Yao Ho, Chew Yen Phang, Ian Tatt Liew, May Ling Lai, Carolyn Shan-Yeu Tien, Sobhana Thangaraju, Marieta Chan, Terence Kee","doi":"10.1111/iji.12639","DOIUrl":"10.1111/iji.12639","url":null,"abstract":"<p>Human leucocyte antigen (HLA) alleles may generate antibodies that are undetectable by routine single-antigen beads (SABs) assays if their unique epitopes are unrepresented. We aimed to describe the prevalence and explore the potential impact of unrepresented HLA alleles in standard SAB kits in our cohort. All individuals who had undergone two-field HLA typing (HLA-A/B/C/DRB1/DQA1/-DQB1/-DPA1/-DPB1) from February 2021 to July 2023 were included. Two-field HLA-DRB3/4/5 typing was imputed. Each unrepresented allele was compared with the most similar represented allele in the standard LABScreen, LABScreen ExPlex (One Lambda) and the LIFECODES (Immucor) SAB kits. Differences in eplet expression (HLA Eplet Registry) were identified. Differences in three-dimensional molecular structures were visualized using generated models (SWISS-MODEL). Two-field HLA typing was performed for 116 individuals. Overall, 16.7% of all HLA alleles, found in 36.2% of individuals, were unrepresented by all SAB test kits. Four eplets, found in 12.9% of individuals, were unrepresented in at least 1 SAB kit. Non-Chinese individuals were more likely to have unrepresented HLA alleles and eplets than Chinese individuals. There were differences in HLA allele and eplet representation amongst the different SAB test kits. Use of supplementary SAB test kits may improve HLA allele and eplet representation. Although some HLA alleles were unrepresented, most epitopes were represented in current SAB kits. However, some unrepresented alleles may contain epitopes which may generate undetectable antibodies. Further studies may be needed to investigate the potential clinical impact of these unrepresented alleles and eplets, especially in certain ethnic populations or at-risk individuals.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 6","pages":"306-315"},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41124179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hai Cheng, Fenglan Sun, Yaoling Ouyang, Chengbin Li
Hepatitis B virus (HBV) is responsible for various liver diseases, such as chronic hepatitis B (CHB), liver fibrosis, liver cirrhosis (LC) and hepatocellular carcinoma (HCC), which pose a significant threat to human health. An ineffective immune response to HBV can result in viral chronicity. Interleukin-37 (IL-37), an immunomodulator, is capable of inhibiting both innate and adaptive immune responses. It is believed that single nucleotide polymorphisms (SNPs) within the IL-37 gene could contribute to the regulation of HBV clearance. Our aim to conduct this study was to investigate whether SNPs in the IL-37 gene were associated with the risk of chronic HBV infection in adults. A total of 342 participants, consisting of 171 cases and 171 controls, were recruited for this study. Sanger sequencing was employed for genotyping six SNPs (rs3811042 G/A, rs3811043 G/C, rs2466449 A/G, rs3811045 C/T, rs3811046 T/G and rs3811047G/A). There was no significant difference in allele and genotype distribution between the two groups, and the constructed haplotypes were not found to be associated with the risk of chronic HBV infection. Our results revealed that there was no relationship between these six SNPs (rs3811042G/A, rs3811043G/C, rs2466449A/G, rs3811045C/T, rs3811046T/G and rs3811047G/A) in the IL-37 gene and susceptibility to chronic HBV infection among Han people in Central China.
{"title":"Correlation analysis of IL-37 gene polymorphisms and susceptibility to chronic HBV infection among Han people in Central China","authors":"Hai Cheng, Fenglan Sun, Yaoling Ouyang, Chengbin Li","doi":"10.1111/iji.12638","DOIUrl":"10.1111/iji.12638","url":null,"abstract":"<p>Hepatitis B virus (HBV) is responsible for various liver diseases, such as chronic hepatitis B (CHB), liver fibrosis, liver cirrhosis (LC) and hepatocellular carcinoma (HCC), which pose a significant threat to human health. An ineffective immune response to HBV can result in viral chronicity. Interleukin-37 (IL-37), an immunomodulator, is capable of inhibiting both innate and adaptive immune responses. It is believed that single nucleotide polymorphisms (SNPs) within the IL-37 gene could contribute to the regulation of HBV clearance. Our aim to conduct this study was to investigate whether SNPs in the IL-37 gene were associated with the risk of chronic HBV infection in adults. A total of 342 participants, consisting of 171 cases and 171 controls, were recruited for this study. Sanger sequencing was employed for genotyping six SNPs (rs3811042 G/A, rs3811043 G/C, rs2466449 A/G, rs3811045 C/T, rs3811046 T/G and rs3811047G/A). There was no significant difference in allele and genotype distribution between the two groups, and the constructed haplotypes were not found to be associated with the risk of chronic HBV infection. Our results revealed that there was no relationship between these six SNPs (rs3811042G/A, rs3811043G/C, rs2466449A/G, rs3811045C/T, rs3811046T/G and rs3811047G/A) in the IL-37 gene and susceptibility to chronic HBV infection among Han people in Central China.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 6","pages":"299-305"},"PeriodicalIF":2.2,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iji.12638","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41125056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jiabin Zhan, Rui Li, Yi Ye, Jing Zheng, Gang Wang, Jinli Wu, Xin Wei, Min Zeng
Allergic rhinitis (AR) is a disease that is difficult to cure and accompanies the patient's life. Proinflammatory cytokines (GM‑CSF and eotaxin) and MUC5AC are key mediators promoting AR progression. Herein, the function of lncRNA ZFAS1 in AR was investigated. Nasal epithelial cells (NECs) were subjected to 50 ng/mL IL-13 for 24 h to construct an AR cell model. The mRNA and protein expressions were assessed using qRT-PCR and western blot. The levels of GM‑CSF, eotaxin, IL-1β, IL-6, TNF-α and MUC5AC in cell supernatant were examined by ELISA. The binding relationships between HDAC3, ZFAS1, miR-7-5p and SIRT1 were analysed using dual luciferase reporter or ChIP assays. Herein, our results displayed that ZFAS1 and SIRT1 were lowly expressed in AR, while miR-7-5p and HDAC3 were highly expressed. Functional experiments displayed that ZFAS1 overexpression suppressed IL-13-induced proinflammatory cytokines and mucin production in NECs. The highly expressed HDAC3 in AR inhibited ZFAS1 expression by binding with ZFAS1 promoter. In addition, our experiments revealed that ZFAS1 targeted miR-7-5p, and miR-7-5p targeted SIRT1. As expected, miR-7-5p overexpression or SIRT1 silencing abrogated ZFAS1 upregulation's repression on IL-13-induced proinflammatory cytokines and MUC5AC secretory levels in NECs. ZFAS1 suppressed proinflammatory cytokines, inflammatory cytokines, and MUC5AC secretory levels in AR by regulating the miR-7-5p/SIRT1 axis. Thus, our work suggested that ZFAS1 might serve as a novel target for AR treatment and prevention.
{"title":"HDAC3-mediated lncRNA ZFAS1 inhibited IL-13-induced secretion of proinflammatory cytokines in nasal epithelial cells by regulating the miR-7-5p/SIRT1 pathway","authors":"Jiabin Zhan, Rui Li, Yi Ye, Jing Zheng, Gang Wang, Jinli Wu, Xin Wei, Min Zeng","doi":"10.1111/iji.12627","DOIUrl":"10.1111/iji.12627","url":null,"abstract":"<p>Allergic rhinitis (AR) is a disease that is difficult to cure and accompanies the patient's life. Proinflammatory cytokines (GM‑CSF and eotaxin) and MUC5AC are key mediators promoting AR progression. Herein, the function of lncRNA ZFAS1 in AR was investigated. Nasal epithelial cells (NECs) were subjected to 50 ng/mL IL-13 for 24 h to construct an AR cell model. The mRNA and protein expressions were assessed using qRT-PCR and western blot. The levels of GM‑CSF, eotaxin, IL-1β, IL-6, TNF-α and MUC5AC in cell supernatant were examined by ELISA. The binding relationships between HDAC3, ZFAS1, miR-7-5p and SIRT1 were analysed using dual luciferase reporter or ChIP assays. Herein, our results displayed that ZFAS1 and SIRT1 were lowly expressed in AR, while miR-7-5p and HDAC3 were highly expressed. Functional experiments displayed that ZFAS1 overexpression suppressed IL-13-induced proinflammatory cytokines and mucin production in NECs. The highly expressed HDAC3 in AR inhibited ZFAS1 expression by binding with ZFAS1 promoter. In addition, our experiments revealed that ZFAS1 targeted miR-7-5p, and miR-7-5p targeted SIRT1. As expected, miR-7-5p overexpression or SIRT1 silencing abrogated ZFAS1 upregulation's repression on IL-13-induced proinflammatory cytokines and MUC5AC secretory levels in NECs. ZFAS1 suppressed proinflammatory cytokines, inflammatory cytokines, and MUC5AC secretory levels in AR by regulating the miR-7-5p/SIRT1 axis. Thus, our work suggested that ZFAS1 might serve as a novel target for AR treatment and prevention.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 6","pages":"281-290"},"PeriodicalIF":2.2,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10224712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p><b><span>Alison Cleaton</span></b>, <i>Emma Burrows, Kimberley Robinson, Michael Richardson, Deborah Pritchard, Tracey Rees</i></p><p><i>Welsh Blood Service, Ely Valley Road, Talbot Green, UK</i></p><p>Regular HLA antibody testing is undertaken for patients awaiting renal transplantation, using LABScreen™ HLA antibody assays. During the COVID-19 pandemic, we observed unexplained changes to some HLA antibody profiles. Investigation revealed that several patients had COVID-19 prior to the changes, therefore, a review of all patients on the transplant waiting list with known COVID-19 infection was undertaken. Sixty-six out of two hundred thirty-seven patients on the transplant waiting list had COVID-19 (March 2020–July 2022). The HLA antibody results from samples prior to and following COVID-19 infection were analysed for changes in existing HLA antibody levels (increased Luminex Median Fluorescent Intensity (MFI) values), or expanded antibody profiles (increased cRF). Fifty-two (78.8%) patients had no detectable change in cRF or MFI; five (7.6%) had changes in MFI (but no change in cRF); nine (13.6%) had changes in MFI and cRF. Two out of nine patients had no recorded prior sensitisation event; four had a previous transplant, four blood transfusions, four pregnancy; and three multiple sensitising events. All nine patients had sustained cRF changes in subsequent samples (follow up to December 2022). Three out of nine patients were consequently identified as having altered immunosuppression due to the COVID-19 infection; these patients had a 20%–76% rise in cRF and now all have a cRF 98%–100%. While the majority of patients awaiting kidney, transplantation had no change to their HLA antibody profile following COVID-19 infection, nine patients had an increase in cRF, which has not been transient. Reduction or withdrawal of immunosuppression to aid recovery from COVID-19 was identified as the cause for three patients.</p><p><b><span>Adrienne Seitz</span></b>, <i>Clive Carter, Brendan Clark, Richard Baker</i></p><p><i>Leeds Teaching Hospitals NHS Trust, Leeds, UK</i></p><p>The level of pre-transplant immune risk is assessed through measuring serum IgG HLA antibodies which can be produced by long lived plasma cells and memory B-cells. Memory B-cells can circulate without producing antibodies, therefore their contribution to the antibody pool may not be fully appreciated. We describe an in vitro method for improving the assessment of pretransplant risk through the non-specific stimulation of peripheral memory B-cells. Peripheral blood mononuclear cells from three unsensitised volunteers and six sensitised patients were cultured for 9 days with the toll-like receptor agonist R848 and interleukin-2. Cell culture supernatant was tested for IgG HLA antibodies using single antigen beads. This was compared with a matched serum sample. Resting Day-0 and stimulated Day-9 B-cell phenotypes were assessed using flow cytometry, confirming the switch to antibody se
{"title":"Oral Abstracts","authors":"","doi":"10.1111/iji.12630","DOIUrl":"https://doi.org/10.1111/iji.12630","url":null,"abstract":"<p><b><span>Alison Cleaton</span></b>, <i>Emma Burrows, Kimberley Robinson, Michael Richardson, Deborah Pritchard, Tracey Rees</i></p><p><i>Welsh Blood Service, Ely Valley Road, Talbot Green, UK</i></p><p>Regular HLA antibody testing is undertaken for patients awaiting renal transplantation, using LABScreen™ HLA antibody assays. During the COVID-19 pandemic, we observed unexplained changes to some HLA antibody profiles. Investigation revealed that several patients had COVID-19 prior to the changes, therefore, a review of all patients on the transplant waiting list with known COVID-19 infection was undertaken. Sixty-six out of two hundred thirty-seven patients on the transplant waiting list had COVID-19 (March 2020–July 2022). The HLA antibody results from samples prior to and following COVID-19 infection were analysed for changes in existing HLA antibody levels (increased Luminex Median Fluorescent Intensity (MFI) values), or expanded antibody profiles (increased cRF). Fifty-two (78.8%) patients had no detectable change in cRF or MFI; five (7.6%) had changes in MFI (but no change in cRF); nine (13.6%) had changes in MFI and cRF. Two out of nine patients had no recorded prior sensitisation event; four had a previous transplant, four blood transfusions, four pregnancy; and three multiple sensitising events. All nine patients had sustained cRF changes in subsequent samples (follow up to December 2022). Three out of nine patients were consequently identified as having altered immunosuppression due to the COVID-19 infection; these patients had a 20%–76% rise in cRF and now all have a cRF 98%–100%. While the majority of patients awaiting kidney, transplantation had no change to their HLA antibody profile following COVID-19 infection, nine patients had an increase in cRF, which has not been transient. Reduction or withdrawal of immunosuppression to aid recovery from COVID-19 was identified as the cause for three patients.</p><p><b><span>Adrienne Seitz</span></b>, <i>Clive Carter, Brendan Clark, Richard Baker</i></p><p><i>Leeds Teaching Hospitals NHS Trust, Leeds, UK</i></p><p>The level of pre-transplant immune risk is assessed through measuring serum IgG HLA antibodies which can be produced by long lived plasma cells and memory B-cells. Memory B-cells can circulate without producing antibodies, therefore their contribution to the antibody pool may not be fully appreciated. We describe an in vitro method for improving the assessment of pretransplant risk through the non-specific stimulation of peripheral memory B-cells. Peripheral blood mononuclear cells from three unsensitised volunteers and six sensitised patients were cultured for 9 days with the toll-like receptor agonist R848 and interleukin-2. Cell culture supernatant was tested for IgG HLA antibodies using single antigen beads. This was compared with a matched serum sample. Resting Day-0 and stimulated Day-9 B-cell phenotypes were assessed using flow cytometry, confirming the switch to antibody se","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 S1","pages":"3-15"},"PeriodicalIF":2.2,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iji.12630","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50130562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The aim of this study was to compare nonrandom associations between physically adjacent single methylation polymorphism loci among rheumatoid arthritis (RA) and normal subjects for investigating RA-risk methylation haplotypes (meplotype). With 354 ACPA-positive RA patients and 335 normal controls selected from a case–control study based on Swedish population, we conducted the first RA epigenome-wide meplotype association study using our software EWAS2.0, mainly including (i) converted the β value to methylation genotype (menotype) data, (ii) identified methylation disequilibrium (MD) block, (iii) calculated frequent of each meplotypes in MD block and performed case–control association test and (iv) screened for RA-risk meplotypes by odd ratio (OR) and p-values. Ultimately, 545 meplotypes on 334 MD blocks were identified significantly associated with RA (p-value < .05). These meplotypes were mapped to 329 candidate genes related to RA. Subsequently, combined with gene optimization, eight RA-risk meplotypes were identified on three risk genes: HLA-DRB1, HLA-DRB5 and HLA-DQB1. Our results reported the relationship between DNA methylation pattern on HLA-DQB1 and the risk of RA for the first time, demonstrating the co-demethylation of ‘cg22984282’ and ‘cg13423887’ on HLA-DQB1 gene (meplotype UU, p-value = 2.90E − 6, OR = 1.68, 95% CI = [1.35, 2.10]) may increase the risk of RA. Our results demonstrates the potential of methylation haplotype analysis to identify RA-related genes from a new perspective and its applicability to the study of other disease.
{"title":"Epigenome-wide methylation haplotype association analysis identified HLA-DRB1, HLA-DRB5 and HLA-DQB1 as risk factors for rheumatoid arthritis","authors":"Jing Xu, Haiyan Chen, Chen Sun, Siyu Wei, Junxian Tao, Zhe Jia, Xingyu Chen, Wenhua Lv, Hongchao Lv, Guoping Tang, Yongshuai Jiang, Mingming Zhang","doi":"10.1111/iji.12637","DOIUrl":"10.1111/iji.12637","url":null,"abstract":"<p>The aim of this study was to compare nonrandom associations between physically adjacent single methylation polymorphism loci among rheumatoid arthritis (RA) and normal subjects for investigating RA-risk methylation haplotypes (meplotype). With 354 ACPA-positive RA patients and 335 normal controls selected from a case–control study based on Swedish population, we conducted the first RA epigenome-wide meplotype association study using our software EWAS2.0, mainly including (i) converted the β value to methylation genotype (menotype) data, (ii) identified methylation disequilibrium (MD) block, (iii) calculated frequent of each meplotypes in MD block and performed case–control association test and (iv) screened for RA-risk meplotypes by odd ratio (OR) and <i>p</i>-values. Ultimately, 545 meplotypes on 334 MD blocks were identified significantly associated with RA (<i>p</i>-value < .05). These meplotypes were mapped to 329 candidate genes related to RA. Subsequently, combined with gene optimization, eight RA-risk meplotypes were identified on three risk genes: HLA-DRB1, HLA-DRB5 and HLA-DQB1. Our results reported the relationship between DNA methylation pattern on HLA-DQB1 and the risk of RA for the first time, demonstrating the co-demethylation of ‘cg22984282’ and ‘cg13423887’ on HLA-DQB1 gene (meplotype UU, <i>p</i>-value = 2.90E − 6, OR = 1.68, 95% CI = [1.35, 2.10]) may increase the risk of RA. Our results demonstrates the potential of methylation haplotype analysis to identify RA-related genes from a new perspective and its applicability to the study of other disease.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 6","pages":"291-298"},"PeriodicalIF":2.2,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10542257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Julio Daimar Oliveira Correa, Francis Maria Báo Zambra, Rafael Tomoya Michita, Mário Reis Álvares-da-Silva, Daniel Simon, José Artur Bogo Chies
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. Chronic HCV infection is also an important cause of hepatic fibrosis, cirrhosis and hepatocellular carcinoma (HCC). HCV has the capacity to evade immune surveillance by altering the host immune response. Moreover, variations in immune-related genes can lead to differential susceptibility to HCV infection as well as interfere on the susceptibility to the development of hepatic fibrosis, cirrhosis and HCC. The human leucocyte antigen G (HLA-G) gene codes for an immunomodulatory protein known to be expressed in the maternal–foetal interface and in immune-privileged tissues. The HLA-G 3′ untranslated region (3′UTR) is important for mRNA stability, and variants in this region are known to impact gene expression. Studies, mainly focusing in a 14 bp insertion/deletion polymorphism, have correlated HLA-G 3′UTR with susceptibility to viral infections, but other polymorphic variants in the HLA-G 3′UTR might also affect HCV infection as they are inherited as haplotypes. The present study evaluated HLA-G 3′UTR polymorphisms and performed linkage disequilibrium test and haplotype assembly in 286 HCV infected patients who have developed fibrosis, cirrhosis or HCC, as well as in 129 healthy control subjects. Haplotypes UTR-1, UTR-2 and UTR-3 were the most observed in HCV+ patients, in the frequencies of 0.276, 0.255 and 0.121, respectively. No statistically significant difference was observed between HCV+ and control subjects, even when patients were grouped according to outcome (HCC, cirrhosis or fibrosis). Despite that, some trends in the results were observed, and therefore, we cannot rule out the possibility that variants associated to high HLA-G expression can be involved in HCV infection susceptibility.
{"title":"HLA-G 3′UTR haplotype analyses in HCV infection and HCV-derived cirrhosis, hepatocellular carcinoma and fibrosis","authors":"Julio Daimar Oliveira Correa, Francis Maria Báo Zambra, Rafael Tomoya Michita, Mário Reis Álvares-da-Silva, Daniel Simon, José Artur Bogo Chies","doi":"10.1111/iji.12636","DOIUrl":"10.1111/iji.12636","url":null,"abstract":"<p>Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. Chronic HCV infection is also an important cause of hepatic fibrosis, cirrhosis and hepatocellular carcinoma (HCC). HCV has the capacity to evade immune surveillance by altering the host immune response. Moreover, variations in immune-related genes can lead to differential susceptibility to HCV infection as well as interfere on the susceptibility to the development of hepatic fibrosis, cirrhosis and HCC. The human leucocyte antigen G (<i>HLA-G</i>) gene codes for an immunomodulatory protein known to be expressed in the maternal–foetal interface and in immune-privileged tissues. The <i>HLA-G</i> 3′ untranslated region (3′UTR) is important for mRNA stability, and variants in this region are known to impact gene expression. Studies, mainly focusing in a 14 bp insertion/deletion polymorphism, have correlated <i>HLA-G</i> 3′UTR with susceptibility to viral infections, but other polymorphic variants in the <i>HLA-G</i> 3′UTR might also affect HCV infection as they are inherited as haplotypes. The present study evaluated <i>HLA-G</i> 3′UTR polymorphisms and performed linkage disequilibrium test and haplotype assembly in 286 HCV infected patients who have developed fibrosis, cirrhosis or HCC, as well as in 129 healthy control subjects. Haplotypes UTR-1, UTR-2 and UTR-3 were the most observed in HCV+ patients, in the frequencies of 0.276, 0.255 and 0.121, respectively. No statistically significant difference was observed between HCV+ and control subjects, even when patients were grouped according to outcome (HCC, cirrhosis or fibrosis). Despite that, some trends in the results were observed, and therefore, we cannot rule out the possibility that variants associated to high <i>HLA-G</i> expression can be involved in HCV infection susceptibility.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 5","pages":"249-255"},"PeriodicalIF":2.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10251930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Manuel Muro-Perez, Gema González-Martínez, Pedro Martínez-García, Isabel Legaz, Pilar Zafrilla, Manuel Muro
Glutathione S‐transferase theta 1 (GSTT1) is an enzyme involved in phase II biotransformation processes and a member of a multigene family of detoxifying and clearing reactive oxygen species. GSTT1 is polymorphic like other biotransforming enzymes, allowing variability in hepatic conjugation processes. Immunological recognition of the GSTT1 alloantigen, as evidenced by donor‐specific antibodies formation, has previously been observed in recipients lacking GSTT1 protein (called GSTT1−, GSTT*0, null phenotype or homozygous for the GSTT1 deletion) who receive liver or kidney transplants from GSTT1+ donors and is a risk factor for the development of de novo hepatitis following liver transplants from a GSTT1 expressing donor. Antibodies against GSTT1 are demonstrated in patients who are GSTT1 null and received a transplant from a GSTT1+ donor. Understanding the local population frequency of the GSTT1 deletion is of value in understanding the potential clinical risk of developing post‐transplant complications, which can be attributed to the nonexpression of GSTT1. A population of 173 healthy donors of the Murcia Region in Southeast Spain was evaluated for a null allele of GSTT1 (n = 173). DNA was extracted, and GSTT‐1 null allele detection was performed by real‐time polymerase chain reaction. The frequency of the null GSTT1 genotype (nonexpression or deletion of the homozygous polymorphism of the GSTT1 protein) was 17.9% (n = 31 null allele GSTT1/173 total individuals). Our data suggest that the frequency of null GSTT1 mutations in our population in Southeast Spain is 17.9%, lower than in other Caucasoid populations. This would convert our recipient population into more susceptible to nonlocal potential organ donors and less susceptible to local donors. All recipients bearing this GSTT1 deletion homozygous would be without the protein and triggering an alloantigen in the case of transplantation with a donor without deletion.
{"title":"Analysis of null deletion polymorphism of glutathione S-transferase theta (GSTT-1), associated with anti-GSTT-1 antibodies development in transplantation","authors":"Manuel Muro-Perez, Gema González-Martínez, Pedro Martínez-García, Isabel Legaz, Pilar Zafrilla, Manuel Muro","doi":"10.1111/iji.12635","DOIUrl":"10.1111/iji.12635","url":null,"abstract":"Glutathione S‐transferase theta 1 (GSTT1) is an enzyme involved in phase II biotransformation processes and a member of a multigene family of detoxifying and clearing reactive oxygen species. GSTT1 is polymorphic like other biotransforming enzymes, allowing variability in hepatic conjugation processes. Immunological recognition of the GSTT1 alloantigen, as evidenced by donor‐specific antibodies formation, has previously been observed in recipients lacking GSTT1 protein (called GSTT1−, GSTT*0, null phenotype or homozygous for the GSTT1 deletion) who receive liver or kidney transplants from GSTT1+ donors and is a risk factor for the development of de novo hepatitis following liver transplants from a GSTT1 expressing donor. Antibodies against GSTT1 are demonstrated in patients who are GSTT1 null and received a transplant from a GSTT1+ donor. Understanding the local population frequency of the GSTT1 deletion is of value in understanding the potential clinical risk of developing post‐transplant complications, which can be attributed to the nonexpression of GSTT1. A population of 173 healthy donors of the Murcia Region in Southeast Spain was evaluated for a null allele of GSTT1 (n = 173). DNA was extracted, and GSTT‐1 null allele detection was performed by real‐time polymerase chain reaction. The frequency of the null GSTT1 genotype (nonexpression or deletion of the homozygous polymorphism of the GSTT1 protein) was 17.9% (n = 31 null allele GSTT1/173 total individuals). Our data suggest that the frequency of null GSTT1 mutations in our population in Southeast Spain is 17.9%, lower than in other Caucasoid populations. This would convert our recipient population into more susceptible to nonlocal potential organ donors and less susceptible to local donors. All recipients bearing this GSTT1 deletion homozygous would be without the protein and triggering an alloantigen in the case of transplantation with a donor without deletion.","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 5","pages":"264-271"},"PeriodicalIF":2.2,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iji.12635","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10547652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study provides the first immunogenetic preliminary evidence that specific human leucocyte antigen (HLA) class I and class II alleles and haplotypes may be relevant for BRCA1 c.5263_5264insC driven oncogenesis. Observed HLA associations might have practical implications for establishment of predictive markers for the response to immunotherapies in malignancies driven by this germ-line mutation.
{"title":"Possible impact of HLA class I and class II on malignancies driven by a single germ-line BRCA1 mutation","authors":"Milena Ivanova, Anastasia Ormandjieva, Rumyana Dodova, Radka Kaneva, Velizar Shivarov","doi":"10.1111/iji.12631","DOIUrl":"10.1111/iji.12631","url":null,"abstract":"<p>This study provides the first immunogenetic preliminary evidence that specific human leucocyte antigen <i>(HLA) class I</i> and <i>class II</i> alleles and haplotypes may be relevant for <i>BRCA1 c.5263_5264insC</i> driven oncogenesis. Observed HLA associations might have practical implications for establishment of predictive markers for the response to immunotherapies in malignancies driven by this germ-line mutation.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 5","pages":"243-248"},"PeriodicalIF":2.2,"publicationDate":"2023-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10186056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is involved in the regulation of immune responses mediated by T cells. This study aimed to explore the correlation between CTLA-4 gene polymorphisms and the risk of gastric cancer (GC) in the Bai minority population of southwestern China. A total of 422 GC patients and 397 healthy controls (HC) were included in this case–control study. Four single nucleotide polymorphism sites of CTLA-4 gene (rs231775, rs733618, rs16840252 and rs3087243) were selected and analysed. The results showed a significant difference in the rs733618 loci between GC and HC groups. The frequency of the rs733618 polymorphism ‘TC’ genotype was significantly lower in GC group compared to the HC group [odds ratio (OR), 95% confidence interval (CI): .47 (.35–.63), p < .001]. GC cases with dominant genetic model ‘TC + CC’ had a 47% reduced risk of GC [OR, 95%CI: .53 (.40–.71), p < .001]. Subgroup analyses revealed that the rs733618 ‘TC + CC’ genotype was associated with a lower risk of GC in male patients [OR, 95%CI: .42 (.31–.58), p < .001], those aged ≤60 years old [OR, 95%CI: .27 (.18–.42), p < .001], non-drinkers [OR, 95%CI: .21 (.13–.33), p < .001], non-smokers [OR, 95%CI: .38 (.25–.57), p < .001] and individuals without Helicobacter pylori infection [OR, 95%CI: .16 (.10–.26), p < .001]. Further multivariated analyses indicated that individuals with the ‘TC + CC’ rs733618 genotype who were aged ≤60 years old [OR, 95%CI: .42 (.29–.83), p = .032] and had no H. pylori infection [OR, 95%CI: .35 (.28–.76), p = .018] were found to have a protective effect against GC. Additionally, soluble CTLA-4 were significantly lower in GC patients with ‘TC’ and ‘TC + CC’ genotypes (all p < .05). Our findings suggest that the rs733618 polymorphism of CTLA-4 gene may play a critical role in the prevention of GC.
细胞毒性T淋巴细胞相关抗原-4 (CTLA-4)参与调节T细胞介导的免疫反应。本研究旨在探讨CTLA-4基因多态性与中国西南白族人群胃癌(GC)发病风险的关系。本病例对照研究共纳入422例胃癌患者和397例健康对照。选择CTLA-4基因的4个单核苷酸多态性位点(rs231775、rs733618、rs16840252和rs3087243)进行分析。结果显示,rs733618位点在GC组和HC组之间存在显著差异。与HC组相比,GC组rs733618多态性“TC”基因型的频率显著降低[优势比(OR), 95%可信区间(CI): 0.47 (0.35 - 0.63), p <措施)。显性遗传模式为“TC + CC”的胃癌患者发生胃癌的风险降低47% [OR, 95%CI: 0.53 (0.40 - 0.71), p <措施)。亚组分析显示,rs733618“TC + CC”基因型与男性患者较低的GC风险相关[OR, 95%CI: 0.42 (0.31 - 0.58), p <.001],年龄≤60岁者[OR, 95%CI: 0.27 (0.18 - 0.42), p <措施,不喝酒(或者,95%置信区间ci: .21 (13 .33), p & lt;措施),非吸烟者(或者,95%置信区间ci: 38 (.25 .57), p & lt;.001]和未感染幽门螺杆菌的个体[OR, 95%CI: 0.16 (0.10 - 0.26), p <措施)。进一步的多变量分析表明,年龄≤60岁[OR, 95%CI: 0.42 (0.29 - 0.83), p = 0.032]且未感染幽门螺杆菌[OR, 95%CI: 0.35 (0.28 - 0.76), p = 0.018]的“TC + CC”rs733618基因型个体对胃癌具有保护作用。此外,可溶性CTLA-4在“TC”和“TC + CC”基因型的GC患者中显著降低(p <.05). 我们的研究结果提示CTLA-4基因rs733618多态性可能在GC的预防中起关键作用。
{"title":"Correlation of CTLA-4 polymorphism and the risk of gastric cancer in a Chinese Bai population","authors":"Ping Yan, Shan Kong, Yong Zheng, Mingjing Cheng, Weidong Zhao","doi":"10.1111/iji.12632","DOIUrl":"10.1111/iji.12632","url":null,"abstract":"<p>Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is involved in the regulation of immune responses mediated by T cells. This study aimed to explore the correlation between CTLA-4 gene polymorphisms and the risk of gastric cancer (GC) in the Bai minority population of southwestern China. A total of 422 GC patients and 397 healthy controls (HC) were included in this case–control study. Four single nucleotide polymorphism sites of CTLA-4 gene (rs231775, rs733618, rs16840252 and rs3087243) were selected and analysed. The results showed a significant difference in the rs733618 loci between GC and HC groups. The frequency of the rs733618 polymorphism ‘TC’ genotype was significantly lower in GC group compared to the HC group [odds ratio (OR), 95% confidence interval (CI): .47 (.35–.63), <i>p</i> < .001]. GC cases with dominant genetic model ‘TC + CC’ had a 47% reduced risk of GC [OR, 95%CI: .53 (.40–.71), <i>p</i> < .001]. Subgroup analyses revealed that the rs733618 ‘TC + CC’ genotype was associated with a lower risk of GC in male patients [OR, 95%CI: .42 (.31–.58), <i>p</i> < .001], those aged ≤60 years old [OR, 95%CI: .27 (.18–.42), <i>p</i> < .001], non-drinkers [OR, 95%CI: .21 (.13–.33), <i>p</i> < .001], non-smokers [OR, 95%CI: .38 (.25–.57), <i>p</i> < .001] and individuals without <i>Helicobacter pylori</i> infection [OR, 95%CI: .16 (.10–.26), <i>p</i> < .001]. Further multivariated analyses indicated that individuals with the ‘TC + CC’ rs733618 genotype who were aged ≤60 years old [OR, 95%CI: .42 (.29–.83), <i>p</i> = .032] and had no <i>H. pylori</i> infection [OR, 95%CI: .35 (.28–.76), <i>p</i> = .018] were found to have a protective effect against GC. Additionally, soluble CTLA-4 were significantly lower in GC patients with ‘TC’ and ‘TC + CC’ genotypes (all <i>p</i> < .05). Our findings suggest that the rs733618 polymorphism of CTLA-4 gene may play a critical role in the prevention of GC.</p>","PeriodicalId":14003,"journal":{"name":"International Journal of Immunogenetics","volume":"50 5","pages":"256-263"},"PeriodicalIF":2.2,"publicationDate":"2023-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10186043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}